NCT05983107 2023-08-09Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast CancerCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Recruiting102 enrolled